Clinical Factors Associated with Decrease in Body weight Induced by treatment with Weekly Semaglutide 1.0mg in Patient with Type 2 Diabetes Mellitus

Clinical Factors Associated with Decrease in Body weight Induced by treatment with Weekly Semaglutide 1.0mg in Patient with Type 2 Diabetes Mellitus - Clinical Factors Associated with Decrease in Body weight Induced by treatment with Weekly Semaglutide 1.0mg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054704

Enrollment

100

Registered

2024-12-31

Start date

2024-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Presence or absence of weight loss of 7% or more 180 days after starting weekly Semaglutide 1.0mg administration.	—

Countries

Japan

Contacts

Public ContactNOBORU KURINAMI

Jinnouchi Hospital Internal Medicine

kurinami@jinnouchi.or.jp0963630011

Outcome results